217 related articles for article (PubMed ID: 29128290)
1. Antibody drug quantitation in coexistence with anti-drug antibodies on nSMOL bioanalysis.
Iwamoto N; Hamada A; Shimada T
Anal Biochem; 2018 Jan; 540-541():30-37. PubMed ID: 29128290
[TBL] [Abstract][Full Text] [Related]
2. Multiplexed monitoring of therapeutic antibodies for inflammatory diseases using Fab-selective proteolysis nSMOL coupled with LC-MS.
Iwamoto N; Takanashi M; Yokoyama K; Yonezawa A; Denda M; Hashimoto M; Tanaka M; Ito H; Matsuura M; Yamamoto S; Honzawa Y; Matsubara K; Shimada T
J Immunol Methods; 2019 Sep; 472():44-54. PubMed ID: 31201793
[TBL] [Abstract][Full Text] [Related]
3. Fully validated LCMS bioanalysis of Bevacizumab in human plasma using nano-surface and molecular-orientation limited (nSMOL) proteolysis.
Iwamoto N; Umino Y; Aoki C; Yamane N; Hamada A; Shimada T
Drug Metab Pharmacokinet; 2016 Feb; 31(1):46-50. PubMed ID: 26830079
[TBL] [Abstract][Full Text] [Related]
4. Validated LC-MS/MS analysis of immune checkpoint inhibitor Nivolumab in human plasma using a Fab peptide-selective quantitation method: nano-surface and molecular-orientation limited (nSMOL) proteolysis.
Iwamoto N; Shimada T; Terakado H; Hamada A
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jun; 1023-1024():9-16. PubMed ID: 27155936
[TBL] [Abstract][Full Text] [Related]
5. Acceleration of nano-surface and molecular-orientation limited (nSMOL) proteolysis with acidified reduction pretreatment for quantification of Tocilizumab.
Iwamoto N; Yonezawa A; Matsubara K; Shimada T
J Pharm Biomed Anal; 2019 Feb; 164():467-474. PubMed ID: 30447535
[TBL] [Abstract][Full Text] [Related]
6. Validated LC/MS Bioanalysis of Rituximab CDR Peptides Using Nano-surface and Molecular-Orientation Limited (nSMOL) Proteolysis.
Iwamoto N; Takanashi M; Hamada A; Shimada T
Biol Pharm Bull; 2016 Jul; 39(7):1187-94. PubMed ID: 27150271
[TBL] [Abstract][Full Text] [Related]
7. LC-MS/MS strategies for therapeutic antibodies and investigation into the quantitative impact of antidrug-antibodies.
Ewles M; Mannu R; Fox C; Stanta J; Evans G; Goodwin L; Duffy J; Bell L; Estdale S; Firth D
Bioanalysis; 2016 Dec; 8(24):2565-2579. PubMed ID: 27884074
[TBL] [Abstract][Full Text] [Related]
8. LC-MS bioanalysis of Trastuzumab and released emtansine using nano-surface and molecular-orientation limited (nSMOL) proteolysis and liquid-liquid partition in plasma of Trastuzumab emtansine-treated breast cancer patients.
Iwamoto N; Shimomura A; Tamura K; Hamada A; Shimada T
J Pharm Biomed Anal; 2017 Oct; 145():33-39. PubMed ID: 28648785
[TBL] [Abstract][Full Text] [Related]
9. Application of nSMOL coupled with LC-MS bioanalysis for monitoring the Fc-fusion biopharmaceuticals Etanercept and Abatacept in human serum.
Iwamoto N; Yokoyama K; Takanashi M; Yonezawa A; Matsubara K; Shimada T
Pharmacol Res Perspect; 2018 Jul; 6(4):e00422. PubMed ID: 30062014
[TBL] [Abstract][Full Text] [Related]
10. Verification between Original and Biosimilar Therapeutic Antibody Infliximab Using nSMOL Coupled LC-MS Bioanalysis in Human Serum.
Iwamoto N; Yokoyama K; Takanashi M; Yonezawa A; Matsubara K; Shimada T
Curr Pharm Biotechnol; 2018; 19(6):495-505. PubMed ID: 29968534
[TBL] [Abstract][Full Text] [Related]
11. Regulated LC-MS/MS bioanalysis technology for therapeutic antibodies and Fc-fusion proteins using structure-indicated approach.
Iwamoto N; Shimada T
Drug Metab Pharmacokinet; 2019 Feb; 34(1):19-24. PubMed ID: 30392772
[TBL] [Abstract][Full Text] [Related]
12. Application of nano-surface and molecular-orientation limited proteolysis to LC-MS bioanalysis of cetuximab.
Iwamoto N; Takanashi M; Umino Y; Aoki C; Hamada A; Shimada T
Bioanalysis; 2016 May; 8(10):1009-20. PubMed ID: 26972866
[TBL] [Abstract][Full Text] [Related]
13. A rapid and universal liquid chromatograph-mass spectrometry-based platform, refmAb-Q nSMOL, for monitoring monoclonal antibody therapeutics.
Iwamoto N; Koguchi Y; Yokoyama K; Hamada A; Yonezawa A; Piening BD; Tran E; Fox BA; Redmond WL; Shimada T
Analyst; 2022 Sep; 147(19):4275-4284. PubMed ID: 35997223
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Bevacizumab Quantification Results in Plasma of Non-small Cell Lung Cancer Patients Using Bioanalytical Techniques Between LC-MS/MS, ELISA, and Microfluidic-based Immunoassay.
Iwamoto N; Takanashi M; Shimada T; Sasaki J; Hamada A
AAPS J; 2019 Aug; 21(6):101. PubMed ID: 31432293
[TBL] [Abstract][Full Text] [Related]
15. A new reliable, transposable and cost-effective assay for absolute quantification of total plasmatic bevacizumab by LC-MS/MS in human plasma comparing two internal standard calibration approaches.
Legeron R; Xuereb F; Chaignepain S; Gadeau AP; Claverol S; Dupuy JW; Djabarouti S; Couffinhal T; Schmitter JM; Breilh D
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Dec; 1070():43-53. PubMed ID: 29111437
[TBL] [Abstract][Full Text] [Related]
16. What sample preparation should be chosen for targeted MS monoclonal antibody quantification in human serum?
Vialaret J; Broutin S; Pugnier C; Santelé S; Jaffuel A; Barnes A; Tiers L; Pelletier L; Lehmann S; Paci A; Hirtz C
Bioanalysis; 2018 May; 10(10):723-735. PubMed ID: 29771137
[TBL] [Abstract][Full Text] [Related]
17. Attribution of the discrepancy between ELISA and LC-MS/MS assay results of a PEGylated scaffold protein in post-dose monkey plasma samples due to the presence of anti-drug antibodies.
Wang SJ; Wu ST; Gokemeijer J; Fura A; Krishna M; Morin P; Chen G; Price K; Wang-Iverson D; Olah T; Weiner R; Tymiak A; Jemal M
Anal Bioanal Chem; 2012 Jan; 402(3):1229-39. PubMed ID: 22130720
[TBL] [Abstract][Full Text] [Related]
18. Critical role of bioanalytical strategies in investigation of clinical PK observations, a Phase I case study.
Peng K; Xu K; Liu L; Hendricks R; Delarosa R; Erickson R; Budha N; Leabman M; Song A; Kaur S; Fischer SK
MAbs; 2014; 6(6):1500-8. PubMed ID: 25484037
[TBL] [Abstract][Full Text] [Related]
19. A multiplexed hybrid LC-MS/MS pharmacokinetic assay to measure two co-administered monoclonal antibodies in a clinical study.
Xu K; Liu L; Maia M; Li J; Lowe J; Song A; Kaur S
Bioanalysis; 2014; 6(13):1781-94. PubMed ID: 25157485
[TBL] [Abstract][Full Text] [Related]
20. Structure-Indicated LC-MS/MS Bioanalysis of Therapeutic Antibodies.
Iwamoto N; Shimada T
Methods Mol Biol; 2022; 2313():187-205. PubMed ID: 34478139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
